Skip to main content
Signal8

Schrodinger, Inc. (SDGR) Form 8-K — Nov 4, 2026

$SDGRForm 8-KItems 2.02, 7.01, 9.01Filed Nov 4, 2026, 4:06 PM ET0001490978-26-000075Original filing

Schrodinger reported Q3 2026 results with ACV of $44.7 million, up 17%, and total revenue of $64.5 million, up 19%, driven by $24.2 million of drug discovery revenue that included a milestone payment from Structure Therapeutics. The company raised full-year 2026 guidance, lifting ACV to $222-232 million (from $218-228 million) and drug discovery revenue to $75-85 million (from $65-75 million). Net loss widened to $37.7 million from $32.8 million, though adjusted EBITDA improved to -$16.8 million from -$33.6 million, and the company held $373 million in cash and securities.

Key figures

Revenue
64491000
Guidance
FY2026 ACV of $222M-$232M (12-17% growth, raised from $218M-$228M); drug discovery revenue $75M-$85M (raised from $65M-$75M); operating expenses expected below 2025.
Revenue Yoy
19%
Cash Position
373000000
Acv q3
$44.7M (+17%)
Adjusted ebitda q3
-$16.8M (vs -$33.6M prior year)
Software revenue q3
$38.2M (+6%)
Operating expenses q3
$64.4M (-13%)
Software gross margin
75%
Operating cash flow 9mo
-$96.5M (vs +$30.0M prior year)
Drug discovery revenue q3
$24.2M (vs $13.0M prior year)
Acv ex contribution growth
24%
Hosted software revenue q3
$17.2M (+49%)

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Schrodinger, Inc. (SDGR) Form 8-K — Nov 4, 2026: AI Analysis | Signal8